Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Cannabinoid receptor ligand" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Novel compounds as cannabinoid receptor ligands
Disclosed herein are cannabinoid receptor ligands of formula (I)wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Owner:ABBVIE INC
Novel compounds as cannabinoid receptor ligands
Disclosed herein are cannabinoid receptor ligands of formula (I)wherein L1, A1, R1g, z, R2, R3, and R4 are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Owner:ABBVIE INC
Novel compounds as cannabinoid receptor ligands
The present application relates to cannabinoid receptor ligands of formula (I)wherein X1, A1, Rx, R2, R3, R4, and z are as defined in the specification. The present application also relates to compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions.
Owner:ABBVIE INC
Novel compounds as cannabinoid receptor ligands
InactiveUS20080287510A1Organic active ingredientsBiocideCannabinoid receptorCannabinoid receptor ligand
Owner:ABBVIE INC
Novel compounds as cannabinoid receptor ligands
Disclosed herein are cannabinoid receptor ligands of formula (I)wherein A1, A5, Rx, X4, and z are as defined in the specification. Compositions comprising such compounds, and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Owner:ABBVIE INC
Imidazole compounds and uses thereof
InactiveUS20050026983A1Not affect characteristicBiocideOrganic active ingredientsDiseaseBiochemistry
Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the activation of the cannabinoid receptors in animals are described herein.
Owner:PFIZER INC
Compounds as cannabinoid receptor ligands
Owner:ABBVIE INC
Compounds as cannabinoid receptor ligands
Owner:ABBVIE INC
Compounds as cannabinoid receptor ligands and uses thereof
Owner:ABBVIE INC
Compounds as cannabinoid receptor ligands
Disclosed herein are cannabinoid receptor ligands of formula (I)wherein A1 and Rx are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Owner:ABBVIE INC
Compounds as cannabinoid receptor ligands
Owner:ABBVIE INC
Compounds as cannabinoid receptor ligands
Cannabinoid receptor ligands of formula (I)wherein Ring A and R1 are as defined in the specification. Compositions including such compounds, and methods of treating conditions and disorders using such compounds and compositions are also described.
Owner:ABBVIE INC
Indoles are cannabinoid receptor ligands
Owner:ABBVIE INC
Bicyclic CB2 cannabinoid receptor ligands
The present invention relates to non-classical cannabinoids that are ligands of the peripheral cannabinoid receptor CB2, and to pharmaceutical compositions thereof comprising as an active ingredient novel (+) alpha-pinene derivatives, which are useful for prevention and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, diabetes mellitus type I, hepatitis, psoriasis, tissue rejection in organ transplants, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, pain including peripheral, visceral, neurophathic inflammatory and referred pain, muscle spasticity, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, neurological disorders including stroke, migraine and cluster headaches, neurodegenerative diseases including Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's chorea, prion-associated neurodegeneration, CNS poisoning and certain types of cancer.
Owner:PHARMOS
Novel compounds as cannabinoid receptor ligands
Owner:ABBVIE INC
Proline analogs as ligands for cannabinoid receptors
ActiveUS20090291947A1Organic active ingredientsSenses disorderCannabinoid receptor ligandIndividual animal
The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.
Owner:PURDUE PHARMA LP
Cannabinoid receptor ligands and uses thereof
Compounds of Formula (I) and (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
Owner:PFIZER PRODS ETAT DE CONNECTICUT
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
Owner:GLENMARK PHARMA SA
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
InactiveUS20080200501A1Suitable for treatmentReducing tobacco cravingBiocideSenses disorderDiseaseCannabinoid
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMA SA
Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMA SA
Novel compounds as cannabinoid receptor ligands and uses thereof
Owner:ABBVIE INC
Methods of treatment of inflammation of the gut
InactiveUS20170112787A1Improving immune homeostasisRelieve symptomsPharmaceutical delivery mechanismAmide active ingredientsDiseaseAutoimmune disease
Described herein are methods of improving immune homeostasis in the gut of a subject suffering from an autoimmune disease characterized by inflammation of the gut by administering, e.g., orally administering, to the subject an effective amount of a cannabinoid receptor agonist to improve immune homeostasis in the gut of the subject. Exemplary cannabinoid receptor ligands include Anandamide. The methods are particularly useful to treat gut inflammation associated with diabetes mellitus Type I.
Owner:UNIV OF CONNECTICUT
Compounds as cannabinoid receptor ligands
InactiveCN102448957AOrganic active ingredientsNervous disorderCannabinoid receptorCannabinoid receptor ligand
Owner:ABBOTT LAB INC
Compounds as cannabinoid receptor ligands
Owner:ABBVIE INC
Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenerative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMA SA
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMACEUTICALS LIMITED
Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
The present invention relates to novel cannabinoid receptor modulators, in particular cannahinoid I (CB1) or cannabinoid 2 (CH2) receptor modulators, and uses thereof for treating diseases, conditions and / or disorders modulated by a cannabinoid receptor (such as pain, neurodegenerative disorders, eating disorders, weight loss or control, and obesity).
Owner:GLENMARK PHARMACEUTICALS LIMITED
2-iminoisothiazole derivatives as cannabinoid receptor ligands
InactiveCN101765593AOrganic active ingredientsNervous disorderCannabinoid receptorCannabinoid receptor ligand
Owner:ABBOTT LAB INC
Bicyclic CB2 cannabinoid receptor ligands
InactiveCN1627939AHalogenated hydrocarbon active ingredientsNervous disorderCannabinoid Receptor CB2Autoimmune condition
The present invention relates to atypical cannabinoids, i.e. ligands of the peripheral cannabinoid receptor CB2, and pharmaceutical compositions thereof comprising novel (+) α-pinene derivatives as active ingredients, which are useful in the prophylaxis of and treatment of autoimmune diseases including but not limited to rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, myasthenia gravis, type I diabetes, hepatitis, psoriasis and immune Associated disorders, including but not limited to tissue rejection in organ transplantation, malabsorption syndromes such as celiac disease, pulmonary diseases such as asthma and Sjögren's syndrome, inflammation including inflammatory bowel disease, including peripheral, visceral, neurological Sexual, inflammatory and associated pain, muscle spasms, cardiovascular disorders including arrhythmia, hypertension and myocardial ischemia, nervous system disorders including stroke, migraine and cluster headaches, including Parkinson's disease, Neurodegenerative diseases like Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, prion-related neurodegeneration, CNS poisoning, and certain types of cancer.
Owner:PHARMOS
Process for preparing cannabinoid receptor ligands
InactiveUS20110144343A1Nervous disorderOrganic chemistryCannabinoid receptorCannabinoid receptor ligand
Owner:ABBVIE INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com